Modified and stabilized GDF propeptides and uses thereof

• US 7,737,116 B2
• Filed: 12/21/2006
• Issued: 06/15/2010
• Est. Priority Date: 02/08/2001
• Status: Expired due to Fees

• Current Assignee: Wyeth LLC (Pfizer Inc.)
• Original Assignee: Wyeth (Pfizer Inc.)
• Inventors: Khor, Soo-Peang, Wolfman, Neil M., Tomkinson, Kathleen N.
• Primary Examiner(s): WOODWARD, CHERIE MICHELLE
• Application Number:
  US11/614,702
• Publication Number:
  US 20070149455A1
• Time in Patent Office: 1,272 Days
• Field of Search: None
• US Class Current: 514/4.8
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 21/06 Anabolic agents androgens A61P5/26
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators
• CPC Class Codes: C07K 14/51 Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).

Claims

1. An isolated BMP-11 propeptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:

11 and has a mutation corresponding to the aspartate residue at position 98 of SEQ ID NO;

11.

4. The BMP-11 propeptide as in any one of claims 1, 2, and 3, wherein the BMP-11 propeptide has an increased in vivo or in vitro half-life relative to a corresponding unmodified BMP-11 propeptide.

5. The BMP-11 propeptide as in any one of claims 1, 2, and 3, wherein the mutation corresponding to the aspartate residue at position 98 of SEQ ID NO:

11 is a substitution mutation.

6. The BMP-11 propeptide as in any one of claims 1, 2, and 3, wherein the mutation corresponding to the aspartate residue at position 98 of SEQ ID NO:

11 is an insertion mutation.

7. The BMP-11 propeptide as in any one of claims 1, 2, and 3, wherein the mutation corresponding to the aspartate residue at position 98 of SEQ ID NO:

11 is a deletion mutation.

8. The BMP-11 propeptide as in any one of claims 1, 2, and 3, wherein the mutation results in the expression of an alanine corresponding to position 98 of SEQ ID NO:

11.

9. The BMP-11 propeptide as in any one of claims 1, 2, and 3, further comprising an Fc region of an IgG molecule.

10. The BMP-11 propeptide of claim 9, wherein the IgG molecule is IgG1 or IgG4.

11. The BMP-11 propeptide of claim 9, wherein the amino acid sequence of the IgG molecule is at least 95% identical to SEQ ID NO:

16.

12. The BMP-11 propeptide of claim 9, wherein the BMP-11 propeptide is fused to the Fc region of the IgG molecule via a linker peptide.

13. The BMP-11 propeptide as in any one of claims 1, 2, and 3, further comprising an altered glycosylation site.

14. The BMP-11 propeptide as in any one of claims 1, 2, and 3, further comprising at least one carbohydrate moiety.

15. The BMP-11 propeptide as in any one of claims 1, 2, and 3, further comprising albumin.

16. The BMP-11 propeptide as in any one of claims 1, 2, and 3, further comprising a nonproteinaceous polymer.

17. The BMP-11 propeptide as in any one of claims 1, 2, and 3, wherein the BMP-11 propeptide further comprises an immunoglobulin molecule.

18. A pharmaceutical composition comprising the BMP-11 propeptide as in any one of claims 1, 2, and 3, and a pharmaceutically acceptable excipient.

19. The BMP-11 propeptide according to any one of claims 1, 2, and 3 wherein the mutation inactivates a proteolytic cleavage site.

2. An isolated BMP-11 propeptide comprising an amino acid sequence that is at least 85% identical to SEQ ID NO:

11, wherein the BMP-11 propeptide has a mutation corresponding to the aspartate residue at position 98 of SEQ ID NO;

11.

3. A BMP-11 propeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:

11 and has a mutation at the aspartate residue corresponding to position 98 of SEQ ID NO;

11.

20. A BMP-11 propeptide comprising a non-human mammalian BMP-11 propeptide homolog of SEQ ID NO:

11, wherein the propeptide has a mutation that modifies an aspartate residue corresponding to position 98 of SEQ ID NO;

11.

21. A method of treating a patient suffering from a muscular or neuromuscular disease or disorder comprising:

administering a therapeutically effective amount of a BMP-11 propeptide that has a mutation that modifies the aspartate residue corresponding to aspartate 98 of SEQ ID NO;

11 and a pharmaceutically acceptable excipient to said patient, wherein the BMP-11 propeptide comprises an amino acid sequence that is at least 85% identical to SEQ ID NO;

11 and has a mutation that modifies the aspartate residue corresponding to position 98 of SEQ ID NO;

11, thereby treating a patient suffering from the muscular or neuromuscular disease or disorder.

22. The method of claim 21, wherein the BMP-11 propeptide has an increased in vivo or in vitro half life relative to a corresponding unmodified BMP-11 propeptide.

23. The method of claim 21, wherein the BMP-11 propeptide further comprises an Fc region of an IgG molecule.

24. The method of claim 23, wherein the IgG molecule is IgG1 or IgG4, or a derivative of IgG1 or IgG4.

25. The method of claim 23, wherein the Fc region of an IgG molecule is at least 95% identical to SEQ ID NO:

16.

26. The method of claim 21, wherein the muscular or neuromuscular disorder is muscular dystrophy.

27. The method of claim 21, wherein the muscular or neuromuscular disorder is amyotrophic lateral sclerosis.

28. The method of claim 21, wherein the muscular or neuromuscular disorder is selected from the group consisting of muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, and cachexia.

29. A method of treating a patient suffering from a metabolic disorder or disease resulting from abnormal glucose homeostasis, comprising administering a therapeutically effective amount of a BMP-11 propeptide that has a mutation that modifies the aspartate residue corresponding to aspartate 98 of SEQ ID NO:

11 and a pharmaceutically acceptable excipient to said patient, wherein the BMP-11 propeptide comprises an amino acid sequence that is at least 85% identical to SEQ ID NO;

11 and has a mutation that modifies the aspartate residue corresponding to position 98 of SEQ ID NO;

11, thereby treating the metabolic disease or disorder.

30. The method of claim 29, wherein the metabolic disorder or disease is selected from the group consisting of type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, and obesity.

31. A method of treating a patient suffering from a bone degenerative disorder, comprising administering a therapeutically effective amount of a BMP-11 propeptide that has a mutation that modifies the aspartate residue corresponding to aspartate 98 of SEQ ID NO:

11 and a pharmaceutically acceptable excipient to said patient, wherein the BMP-11 propeptide comprises an amino acid sequence that is at least 85% identical to SEQ ID NO;

11 and has a mutation that modifies the aspartate residue corresponding to position 98 of SEQ ID NO;

11, thereby treating the bone degenerative disorder.

32. The method of claim 31, wherein the bone degenerative disorder is osteoporosis.